Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(40%)

Phase Distribution

No phase data available

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(1)
Terminated(3)
Other(1)

Detailed Status

Terminated2
Completed1
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
33.3%

Trials by Status

completed120%
terminated240%
unknown120%
withdrawn120%

Recent Activity

0 active trials
Showing 5 of 5
terminated

Plasma Concentration of Biological Markers in Placenta Accreta Spectrum

NCT04525534
completed

Fetal Exposure to Cannabinoids: Exposure, Methylation and Neurodevelopmental Effects

NCT04422600
withdrawn

Physiological Abnormalities Associated with Down Syndrome

NCT03087500
terminated

Plasma Concentration of Biological Markers in Placental Abruption

NCT03782168
unknown

Metabolomics Explores Biomarkers for Metastatic Breast Cancer

NCT04302415

Clinical Trials (5)

Showing 5 of 5 trials
NCT04525534

Plasma Concentration of Biological Markers in Placenta Accreta Spectrum

Terminated
NCT04422600

Fetal Exposure to Cannabinoids: Exposure, Methylation and Neurodevelopmental Effects

Completed
NCT03087500

Physiological Abnormalities Associated with Down Syndrome

Withdrawn
NCT03782168

Plasma Concentration of Biological Markers in Placental Abruption

Terminated
NCT04302415

Metabolomics Explores Biomarkers for Metastatic Breast Cancer

Unknown

All 5 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
5